About this item:

90 Views | 32 Downloads

Author Notes:

fpasque@emory.edu

AMY, DCK, and FJP conceptualized the study and wrote the first draft. AMY, JH, AA, and GMB conducted the data extraction for the systematic review. SD carried out the resource search. AMY, JH, AA, GMB, MAU, JDB, KTN, NYX, TS, JYZ, reviewed the literature for the COVIDindiabetes.org webstite. DCK, GD, and FJP supervised the website development and content.

We would like to thank the contributors to our website including: Alyson Myers, MD (USA); Daniel Rubin, MD, MS (USA); Darin Olson, MD, PhD (USA); David Lam, MD (USA); Deborah Wake, MBChB, BSc, PhD, Clin Ed Dip (UK); Emilia Gómez Hoyos, PhD (Spain); Faisal A. Aljehani, MBBS (USA); Fernando Gomez-Peralta, MD, PhD (Spain); Gerry Rayman, MD, FRCP (UK); Guillermo E. Umpierrez, MD, CDE (USA); Javier Carrasco, MD, PhD (Spain); Jose Luis Paz-Ibarra, MD (Peru); Katalina Funke, MD (USA); Kathie L. Hermayer, MD, MS (USA); Kathleen Dungan, MD, MPH (USA); Ketan Dhatariya, MBBS, MSc, PhD (UK); Lillian F. Lien, MD (USA); Marcos Tadashi K. Toyoshima, MD (Brazil); Maya Fayfman, MD (USA); Marie McDonnell, MD (USA); Miguel Pasquel, MD (Ecuador); Mihail Zilbermint, MD, FACE (USA); Mohammed Al-Sofiani, MD, MSc (Saudi Arabia); Nadine E. Palermo, DO (USA); Omar G. Mustafa, MBChB, MRCP (UK); Paul Szumita, PharmD (USA); Priyathama Vellanki, MD (USA); Ricardo Gomez-Huelgas, MD (Spain); Rodolfo J. Galindo, MD, FACE (USA); Shivani Agarwal, MD, MPH (USA); Silvio E. Inzucchi, MD (USA). We also thank our website developer Javier Szyszlican.

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DCK is a consultant to Better Therapeutics, EOFlow, Integrity, Lifecare, Nevro, Novo Nordisk, Sanofi, and Thirdwayv. GMD has received research support from Insulet Corp. and consulting fees from Medscape. FJP has received unrestricted research support (to Emory University) from Insulet, Ideal Medical Technologies, Dexcom, Novo Nordisk, and Tandem Diabetes Care and consulting fees from Dexcom and Medscape. All other authors have nothing relevant to disclose.

Subjects:

Research Funding:

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This effort was partially supported by NIDDK of the NIH under the award number P30DK111024, Georgia Diabetes Translation Research Center (GDTRC) project “The Preparedness Cycle in the Care of People with Diabetes During the COVID-19 Pandemic and Future Outbreaks”.

Keywords:

  • COVID-19
  • continuous glucose monitoring
  • hyperglycemia
  • inpatient diabetes
  • remote monitoring
  • telehealth
  • virtual care
  • Humans
  • COVID-19
  • Pandemics
  • Blood Glucose Self-Monitoring
  • Blood Glucose
  • Telemedicine
  • Diabetes Mellitus

Diabetes Research and Resource Sharing During the COVID-19 Pandemic: A Systematic Review and Experience from an Academic/Non-profit Resource Website

Show all authors Show less authors

Tools:

Journal Title:

Journal of Diabetes Science and Technology

Volume:

Volume 17, Number 5

Publisher:

, Pages 1284-1294

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: The magnitude of the response of the diabetes professional community to the COVID-19 pandemic is not known. We aimed to examine diabetes technology research trends and resources offered by professional organizations during this period. Methods: We explored patterns of the response from the professional diabetes community to the pandemic by (1) systematically searching for articles related to diabetes, COVID-19, and diabetes technologies; (2) examining publication trends of research protocols (clinicaltrials.gov) and preprints (medRxiv); and (3) reviewing online resources from professional organizations including our website (COVIDinDiabetes.org; an Emory University—Diabetes Technology Society collaboration). Results: We identified 492 articles published between December 2019 and December 2022 meeting our inclusion criteria. Telemedicine and continuous glucose monitoring were the most common reported technologies from most parts of the world. The largest number of preprint articles was published in 2020, with a decline in 2021 and 2022. The number of research protocols related to COVID-19 was the highest in 2020 and declined in 2021 and 2022. Resources from organizations included protocols adapted to treat patients with diabetes and COVID-19, training programs, emergency preparedness, and literature on diabetes and COVID-19. On our website (COVIDinDiabetes.org), there were 12 236 visits and 18 149 pageviews, with 1.6 actions per visits, with most visits coming from North America (N = 7233, 54.2%), South America (N = 2663, 21.8%), and Europe (N = 1219). Conclusions: We conclude that the COVID-19 pandemic promoted unprecedented global research productivity related to diabetes and COVID-19 and that the transition to the use of technology resources has been evident during this period.

Copyright information:

© 2023 Diabetes Technology Society

Export to EndNote